Juniper Pharma COL-1077 Phase 1 data published

Juniper Pharmaceuticals

The peer-reviewed medical journal, Clinical Pharmacology in Drug Development, has published the combined results of two Phase 1 clinical trials by Juniper Pharmaceuticals (NASDAQ:JNP) that demonstrated the safety and pharmacokinetics of Juniper’s lidocaine bioadhesive vaginal gel, COL-1077.

The article reports that in women treated with COL-1077, lidocaine was absorbed through vaginal tissue and into the systemic circulation in a dose-proportional manner, with little systemic accumulation.

Plasma concentrations were 10- to 20-fold lower than those seen for intravenous lidocaine when administered for its anti-arrhythmic activity, thus demonstrating a wide safety margin for COL-1077.

“These positive PK and safety studies demonstrate that COL-1077 effectively delivered lidocaine while maintaining relatively low serum levels of the drug,” Dr. Bridget Martell, CMO of Juniper and lead author of the paper, said in a statement.

“This combination of systemic absorption through local tissue administration with low lidocaine plasma concentrations suggests a unique safety-benefit profile for the product,” she added.

Juniper is currently completing a Phase 2b clinical trial evaluating COL-1077 10% lidocaine bioadhesive vaginal gel as a self-administered analgesic for minimally invasive outpatient gynecologic procedure pain.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.